A Phase 3 interventional study of RoActemra/Actemra (tocilizumab) in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Terminated at 11 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2018-02-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment is 104 weeks.
3,554 studies on the registry are indexed under Arthritis; 318 are open to participants now.
This study's enrollment of 41 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: RoActemra/Actemra (tocilizumab)
Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
Percentage of Participants With Adverse Events (AEs)
AE: unfavorable and unintended sign, symptom, or disease associated with use of treatment, regardless of treatment relation. Pre-existing conditions that worsened and laboratory or clinical tests that resulted in change in treatment or discontinuation from treatment were reported as AEs. Serious AE: resulted in death, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically significant. Severe AE: AE that caused inability to work or perform normal daily activity. AEs of special interest: Serious infections (including opportunistic infections), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related AE, Malignant neoplasms, Anaphylaxis event, Demyelination-related events, Stroke, Spontaneous or serious bleeding, Serious/medically significant hepatic events. Any AE included serious and non-serious AE.
Time frame: Baseline to 12 weeks after last actual study medication (up to 101 weeks)
Percentage of Participants With JIA ACR 30 Response at Weeks 12, 24 and End of Follow Up
JIA ACR30 response was defined as 3 of any 6 core outcome variables improved by at least 30% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: Physician global assessment (PGA) of disease activity using Visual Analog Scale (VAS) from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); Patient/parent global assessment (PtGA) of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and Erythrocyte Sedimentation Rate (ESR).
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Percentage of Participants With JIA ACR 50 Response at Weeks 12, 24 and End of Follow up
JIA ACR50 response was defined as 3 of any 6 core outcome variables improved by at least 50% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Percentage of Participants With JIA ACR 70 Response at Weeks 12, 24 and End of Follow up
JIA ACR70 response was defined as 3 of any 6 core outcome variables improved by at least 70% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Percentage of Participants With JIA ACR 90 Response at Weeks 12, 24 and End of Follow up
JIA ACR90 response was defined as 3 of any 6 core outcome variables improved by at least 90% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Percentage of Participants With Inactive Disease at Week 12, 24 and End of Follow up
Criteria for Inactive Disease: 1) No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both), 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal ESR (less than \[\<\] 20 millimeters per hour \[mm/hour\]), and 4) PGA of disease activity using VAS indicated no disease activity (where no disease activity is considered to be a score less than or equal to \[≤\]10 mm on a 100 mm VAS where left end of line 0 \[inactive arthritis\] to right end of line 100 \[very active arthritis\]).
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Percentage of Participants With Clinical Remission at Week 12, 24 and End of Follow up
Clinical remission: inactive disease for minimum of 6 continuous months while on medication (Level 1); off oral corticosteroid medications but still on tocilizumab (Level 2); off both methotrexate and oral corticosteroids but still on tocilizumab (Level 3); or off all anti-arthritis medications-oral corticosteroids, methotrexate, non-steroidal anti-inflammatory drugs but still on tocilizumab (Level 4). Inactive disease: No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to sJIA; Normal ESR (\<20 mm/hour); PGA of disease activity indicated no disease activity (score ≤10 mm on a 100 mm VAS where 0 \[inactive arthritis\] and 100 \[very active arthritis\]). Overall percentage of participants with clinical remission (any level) are reported.
Time frame: Baseline, Week 12, 24, End of Follow up (up to 101 weeks)
Change From Baseline in Joints With Active Arthritis at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
Joint with active arthritis was defined as a joint with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in Number of Joints With Limitation of Movement at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
The maximum number of joints with limitation of movement is 67 and these were defined as those with 'limitation of motion'.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in PGA of Disease Activity at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
The physician provides a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. A higher score indicates more disease activity. A negative change score indicates improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in PtGA of Overall Well-Being at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
The participant or parent/guardian, as appropriate, provides a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (ie, maximum arthritis disease activity). A higher score indicates poorer well-being. A negative change score indicates improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in ESR at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in Childhood Health Assessment - Disability Index (CHAQ-DI) at Weeks 12, 24, 36, 48, 60, 72, 84, End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Percentage of Participants With Minimally Important Improvement in the CHAQ-DI Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. A minimally important improvement was defined as at least a 0.13 improvement in CHAQ-DI score from baseline.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Activitiy) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Activity component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Arising) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Arising component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Dressing and Grooming) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Dressing and Grooming component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Eating) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Eating component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Grip) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Grip component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Hygiene) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Hygiene component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Reach) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Reach component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Change From Baseline in CHAQ-DI (Walking) Score at Weeks 12, 24, 36, 48, 60, 72, 84 and End of Follow up
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Walking component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, End of follow up (up to 101 weeks)
Absolute C-Reactive Protein Levels
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, End of follow up (up to 101 weeks)
| Milestone | Tocilizumab |
|---|---|
| Started | 41 |
| Completed | 0 |
| Not completed | 41 |
| Withdrew: Adverse event | 1 |
| Withdrew: Study terminated by sponsor | 40 |
AE: unfavorable and unintended sign, symptom, or disease associated with use of treatment, regardless of treatment relation. Pre-existing conditions that worsened and laboratory or clinical tests that resulted in change in treatment or discontinuation from treatment were reported as AEs. Serious AE: resulted in death, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically significant. Severe AE: AE that caused inability to work or perform normal daily activity. AEs of special interest: Serious infections (including opportunistic infections), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related AE, Malignant neoplasms, Anaphylaxis event, Demyelination-related events, Stroke, Spontaneous or serious bleeding, Serious/medically significant hepatic events. Any AE included serious and non-serious AE.
| percentage of participants | Tocilizumab |
|---|---|
| Any AEs | 56.1 |
| Any Treatment Related AEs | 29.3 |
| Any SAEs | 7.3 |
| Any Severe AEs | 2.4 |
| Any Life Threatening AEs | 0.0 |
| AEs of Special Interest | 0.0 |
| AE Leading to Dosage Modification/Interruption | 22.0 |
| Withdrawal Due to AEs | 2.4 |
| Withdrawal Due to SAEs | 2.4 |
| Withdrawal Due to AEs of Special Interest | 0.0 |
JIA ACR30 response was defined as 3 of any 6 core outcome variables improved by at least 30% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: Physician global assessment (PGA) of disease activity using Visual Analog Scale (VAS) from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); Patient/parent global assessment (PtGA) of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and Erythrocyte Sedimentation Rate (ESR).
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 100.0 (91.4 to 100.0) |
| Week 12 | 100.0 (91.4 to 100.0) |
| Week 24 | 100.0 (91.4 to 100.0) |
| Follow up | 80.5 (65.1 to 91.2) |
JIA ACR50 response was defined as 3 of any 6 core outcome variables improved by at least 50% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 100.0 (91.4 to 100.0) |
| Week 12 | 100.0 (91.4 to 100.0) |
| Week 24 | 100.0 (91.4 to 100.0) |
| Follow up | 80.5 (65.1 to 91.2) |
JIA ACR70 response was defined as 3 of any 6 core outcome variables improved by at least 70% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 100.0 (91.4 to 100.0) |
| Week 12 | 100.0 (91.4 to 100.0) |
| Week 24 | 97.6 (87.1 to 99.9) |
| Follow up | 78.0 (62.4 to 89.4) |
JIA ACR90 response was defined as 3 of any 6 core outcome variables improved by at least 90% of the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%. Six core variables were: PGA of disease activity using VAS from left end of line 0 (inactive arthritis) to right end of line 100 (very active arthritis); PtGA of overall well-being using a VAS from left end of line 0 (very well) to right end of line 100 (very poor); Number of joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); Number of joints with limitation of movement; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and ESR.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 73.2 (57.1 to 85.8) |
| Week 12 | 78.0 (62.4 to 89.4) |
| Week 24 | 80.5 (65.1 to 91.2) |
| Follow up | 75.6 (59.7 to 87.6) |
Criteria for Inactive Disease: 1) No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both), 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal ESR (less than \[\<\] 20 millimeters per hour \[mm/hour\]), and 4) PGA of disease activity using VAS indicated no disease activity (where no disease activity is considered to be a score less than or equal to \[≤\]10 mm on a 100 mm VAS where left end of line 0 \[inactive arthritis\] to right end of line 100 \[very active arthritis\]).
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 63.4 (46.9 to 77.9) |
| Week 12 | 65.9 (49.4 to 79.9) |
| Week 24 | 75.6 (59.7 to 87.6) |
| Follow up | 61.0 (44.5 to 75.8) |
Clinical remission: inactive disease for minimum of 6 continuous months while on medication (Level 1); off oral corticosteroid medications but still on tocilizumab (Level 2); off both methotrexate and oral corticosteroids but still on tocilizumab (Level 3); or off all anti-arthritis medications-oral corticosteroids, methotrexate, non-steroidal anti-inflammatory drugs but still on tocilizumab (Level 4). Inactive disease: No joints with active arthritis (joints with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both); No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to sJIA; Normal ESR (\<20 mm/hour); PGA of disease activity indicated no disease activity (score ≤10 mm on a 100 mm VAS where 0 \[inactive arthritis\] and 100 \[very active arthritis\]). Overall percentage of participants with clinical remission (any level) are reported.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline | 43.9 (28.5 to 60.3) |
| Week 12 | 46.3 (30.7 to 62.6) |
| Week 24 | 48.8 (32.9 to 64.9) |
| Follow up | 46.3 (30.7 to 62.6) |
Joint with active arthritis was defined as a joint with swelling not due to deformity or joints with limitation of motion and with pain, tenderness or both.
| Joints | Tocilizumab |
|---|---|
| Baseline (n=41) | 1.4 ± 2.68 |
| Change From Baseline at Week 12 (n=41) | -0.1 ± 1.70 |
| Change From Baseline at Week 24 (n=41) | -0.4 ± 4.56 |
| Change From Baseline at Week 36 (n=35) | -1.4 ± 2.80 |
| Change From Baseline at Week 48 (n=22) | -1.7 ± 3.34 |
| Change From Baseline at Week 60 (n=17) | 0.4 ± 8.17 |
| Change From Baseline at Week 72 (n=10) | 1.9 ± 7.52 |
| Change From Baseline at Week 84 (n=7) | 3.9 ± 11.55 |
| Change From Baseline at Follow Up (n=33) | 1.2 ± 4.14 |
The maximum number of joints with limitation of movement is 67 and these were defined as those with 'limitation of motion'.
| Joints | Tocilizumab |
|---|---|
| Baseline (n=41) | 3.5 ± 6.30 |
| Change From Baseline at Week 12 (n=41) | -0.6 ± 2.23 |
| Change From Baseline at Week 24 (n=41) | -0.9 ± 2.75 |
| Change From Baseline at Week 36 (n=35) | -1.3 ± 3.14 |
| Change From Baseline at Week 48 (n=22) | -1.5 ± 4.21 |
| Change From Baseline at Week 60 (n=17) | -1.2 ± 5.10 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 1.83 |
| Change From Baseline at Week 84 (n=7) | 0.7 ± 3.09 |
| Change From Baseline at Follow Up (n=33) | 2.6 ± 5.80 |
The physician provides a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. A higher score indicates more disease activity. A negative change score indicates improvement.
| mm | Tocilizumab |
|---|---|
| Baseline (n=41) | 4.5 ± 4.99 |
| Change From Baseline at Week 12 (n=41) | 1.0 ± 5.66 |
| Change From Baseline at Week 24 (n=41) | 0.1 ± 4.97 |
| Change From Baseline at Week 36 (n=35) | -0.6 ± 4.29 |
| Change From Baseline at Week 48 (n=22) | -0.4 ± 5.80 |
| Change From Baseline at Week 60 (n=17) | 0.4 ± 6.52 |
| Change From Baseline at Week 72 (n=10) | 1.0 ± 6.50 |
| Change From Baseline at Week 84 (n=7) | 2.9 ± 13.09 |
| Change From Baseline at Follow Up (n=33) | 4.4 ± 8.65 |
The participant or parent/guardian, as appropriate, provides a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line represents 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (ie, maximum arthritis disease activity). A higher score indicates poorer well-being. A negative change score indicates improvement.
| mm | Tocilizumab |
|---|---|
| Baseline (n=41) | 4.0 ± 5.72 |
| Change From Baseline at Week 12 (n=41) | -0.2 ± 3.31 |
| Change From Baseline at Week 24 (n=41) | -1.5 ± 4.38 |
| Change From Baseline at Week 36 (n=35) | -2.2 ± 4.34 |
| Change From Baseline at Week 48 (n=22) | -2.2 ± 4.89 |
| Change From Baseline at Week 60 (n=17) | -1.2 ± 2.08 |
| Change From Baseline at Week 72 (n=10) | -0.9 ± 1.60 |
| Change From Baseline at Week 84 (n=7) | -0.9 ± 2.19 |
| Change From Baseline at Follow Up (n=33) | 3.2 ± 7.39 |
| millimeters per hour (mm/hour) | Tocilizumab |
|---|---|
| Baseline (n=41) | 5.0 ± 4.08 |
| Change From Baseline at Week 12 (n=41) | -0.95 ± 3.83 |
| Change From Baseline at Week 24 (n=41) | -0.9 ± 5.01 |
| Change From Baseline at Week 36 (n=35) | -1.2 ± 5.26 |
| Change From Baseline at Week 48 (n=22) | -0.9 ± 3.30 |
| Change From Baseline at Week 60 (n=17) | -0.35 ± 5.22 |
| Change From Baseline at Week 72 (n=10) | 0.5 ± 6.88 |
| Change From Baseline at Week 84 (n=7) | 3.3 ± 14.68 |
| Change From Baseline at Follow Up (n=33) | 5.9 ± 8.07 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.1 ± 0.24 |
| Change From Baseline at Week 12 (n=41) | -0.0 ± 0.06 |
| Change From Baseline at Week 24 (n=41) | 0.0 ± 0.09 |
| Change From Baseline at Week 36 (n=35) | -0.0 ± 0.09 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.15 |
| Change From Baseline at Week 60 (n=17) | 0.0 ± 0.08 |
| Change From Baseline at Week 72 (n=10) | -0.1 ± 0.09 |
| Change From Baseline at Week 84 (n=7) | -0.1 ± 0.26 |
| Change From Baseline at Follow Up (n=33) | 0.1 ± 0.25 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. A minimally important improvement was defined as at least a 0.13 improvement in CHAQ-DI score from baseline.
| percentage of participants | Tocilizumab |
|---|---|
| Week 12 | 2.4 (0.1 to 12.9) |
| Week 24 | 2.4 (0.1 to 12.9) |
| Week 36 | 5.7 (0.7 to 19.2) |
| Week 48 | 18.2 (5.2 to 40.3) |
| Week 72 | 10.0 (0.3 to 44.5) |
| Week 84 | 28.6 (3.7 to 71.0) |
| Follow Up | 15.2 (5.1 to 31.9) |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Activity component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=40) | 0.2 ± 0.41 |
| Change From Baseline at Week 12 (n=39) | 0.0 ± 0.16 |
| Change From Baseline at Week 24 (n=39) | 0.0 ± 0.28 |
| Change From Baseline at Week 36 (n=34) | 0.0 ± 0.35 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.35 |
| Change From Baseline at Week 60 (n=17) | -0.1 ± 0.43 |
| Change From Baseline at Week 72 (n=10) | -0.1 ± 0.57 |
| Change From Baseline at Week 84 (n=7) | -0.1 ± 0.38 |
| Change From Baseline at Follow Up (n=33) | -0.1 ± 0.35 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Arising component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.0 ± 0.22 |
| Change From Baseline at Week 12 (n=40) | 0.0 ± 0.23 |
| Change From Baseline at Week 24 (n=40) | 0.0 ± 0.16 |
| Change From Baseline at Week 36 (n=34) | -0.0 ± 0.17 |
| Change From Baseline at Week 48 (n=22) | -0.0 ± 0.21 |
| Change From Baseline at Week 60 (n=17) | -0.1 ± 0.24 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 0.0 |
| Change From Baseline at Week 84 (n=7) | 0.0 ± 0.0 |
| Change From Baseline at Follow Up (n=33) | 0.0 ± 0.17 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Dressing and Grooming component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.1 ± 0.42 |
| Change From Baseline at Week 12 (n=40) | 0.0 ± 0.16 |
| Change From Baseline at Week 24 (n=40) | 0.1 ± 0.22 |
| Change From Baseline at Week 36 (n=34) | 0.1 ± 0.24 |
| Change From Baseline at Week 48 (n=22) | 0.0 ± 0.31 |
| Change From Baseline at Week 60 (n=17) | 0.0 ± 0.35 |
| Change From Baseline at Week 72 (n=10) | -0.2 ± 0.63 |
| Change From Baseline at Week 84 (n=7) | -0.3 ± 0.76 |
| Change From Baseline at Follow Up (n=33) | -0.1 ± 0.50 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Eating component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.1 ± 0.33 |
| Change From Baseline at Week 12 (n=40) | 0.0 ± 0.23 |
| Change From Baseline at Week 24 (n=40) | 0.0 ± 0.23 |
| Change From Baseline at Week 36 (n=34) | 0.0 ± 0.25 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.29 |
| Change From Baseline at Week 60 (n=17) | 0.1 ± 0.24 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 0.0 |
| Change From Baseline at Week 84 (n=7) | -0.1 ± 0.38 |
| Change From Baseline at Follow Up (n=33) | -0.0 ± 0.30 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Grip component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.2 ± 0.40 |
| Change From Baseline at Week 12 (n=40) | -0.1 ± 0.22 |
| Change From Baseline at Week 24 (n=40) | -0.0 ± 0.16 |
| Change From Baseline at Week 36 (n=34) | -0.1 ± 0.29 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.29 |
| Change From Baseline at Week 60 (n=17) | 0.1 ± 0.43 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 0.47 |
| Change From Baseline at Week 84 (n=7) | -0.1 ± 0.38 |
| Change From Baseline at Follow Up (n=33) | -0.1 ± 0.29 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Hygiene component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.2 ± 0.44 |
| Change From Baseline at Week 12 (n=40) | -0.0 ± 0.16 |
| Change From Baseline at Week 24 (n=40) | 0.0 ± 0.16 |
| Change From Baseline at Week 36 (n=34) | -0.1 ± 0.24 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.35 |
| Change From Baseline at Week 60 (n=17) | -0.1 ± 0.43 |
| Change From Baseline at Week 72 (n=10) | -0.1 ± 0.32 |
| Change From Baseline at Week 84 (n=7) | -0.4 ± 0.79 |
| Change From Baseline at Follow Up (n=33) | -0.2 ± 46 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Reach component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.2 ± 0.42 |
| Change From Baseline at Week 12 (n=40) | -0.0 ± 0.28 |
| Change From Baseline at Week 24 (n=40) | -0.1 ± 0.22 |
| Change From Baseline at Week 36 (n=34) | -0.0 ± 0.30 |
| Change From Baseline at Week 48 (n=22) | -0.1 ± 0.29 |
| Change From Baseline at Week 60 (n=17) | 0.1 ± 0.43 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 0.0 |
| Change From Baseline at Week 84 (n=7) | 0.0 ± 0.0 |
| Change From Baseline at Follow Up (n=33) | -0.1 ± 0.38 |
The CHAQ-DI, as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Walking component was measured on 0-3 scale (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do).
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=41) | 0.0 ± 0.16 |
| Change From Baseline at Week 12 (n=40) | 0.0 ± 0.0 |
| Change From Baseline at Week 24 (n=40) | 0.1 ± 0.22 |
| Change From Baseline at Week 36 (n=34) | 0.0 ± 0.0 |
| Change From Baseline at Week 48 (n=22) | 0.0 ± 0.0 |
| Change From Baseline at Week 60 (n=17) | 0.1 ± 0.24 |
| Change From Baseline at Week 72 (n=10) | 0.0 ± 0.0 |
| Change From Baseline at Week 84 (n=7) | 0.0 ± 0.0 |
| Change From Baseline at Follow Up (n=33) | 0.0 ± 0.0 |
| milligrams per Liter | Tocilizumab |
|---|---|
| Baseline (n=40) | 0.9468 ± 4.11395 |
| Week 4 (n=39) | 0.9755 ± 1.71814 |
| Week 8 (n=41) | 1.8995 ± 6.17464 |
| Week 12 (n=41) | 1.7157 ± 3.07714 |
| Week 16 (n=41) | 2.4115 ± 8.71986 |
| Week 20 (n=39) | 0.9706 ± 2.67299 |
| Week 24 (n=41) | 1.4893 ± 3.24038 |
| Week 28 (n=40) | 2.2320 ± 5.51994 |
| Week 32 (n=39) | 2.1713 ± 7.09086 |
| Week 36 (n=35) | 1.6507 ± 4.81621 |
| Week 40 (n=31) | 1.2562 ± 2.49440 |
| Week 44 (n=26) | 1.1710 ± 1.96013 |
| Week 48 (n=22) | 1.2382 ± 1.98754 |
| Week 52 (n=22) | 1.2019 ± 1.71587 |
| Week 56 (n=18) | 3.9651 ± 12.83795 |
| Week 60 (n=17) | 2.6449 ± 8.93648 |
| Week 64 (n=15) | 0.6341 ± 1.40213 |
| Week 68 (n=11) | 0.5210 ± 1.49015 |
| Week 72 (n=10) | 1.5263 ± 1.97617 |
| Week 76 (n=8) | 2.0304 ± 2.49171 |
| Week 80 (n=7) | 1.4975 ± 2.39680 |
| Week 84 (n=7) | 11.4459 ± 25.92600 |
| Week 88 (n=3) | 0.0704 ± 0.06935 |
| Follow up (n=32) | 2.3169 ± 3.24139 |
Collected over Baseline to 12 weeks after last actual study medication (up to 101 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 3/41 (7.3%) | 15/41 (36.6%) |
| Event | Tocilizumab |
|---|---|
| Multiple injuriesInjury, poisoning and procedural complications | 1/41 |
| Neutrophil count decreasedInvestigations | 1/41 |
| ProteinuriaRenal and urinary disorders | 1/41 |
| Event | Tocilizumab |
|---|---|
| PharyngitisInfections and infestations | 6/41 |
| Upper respiratory tract infectionInfections and infestations | 5/41 |
| BronchitisInfections and infestations | 4/41 |
| NeutropeniaBlood and lymphatic system disorders | 3/41 |
Safety Population included all participants who entered the study, took at least one dose of study drug, and with at least one safety follow-up, regardless of premature withdrawal.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 12.0 ± 4.45 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 33 |
| Male | 8 |
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche